BFM
VTVT icon

Boothbay Fund Management’s vTv Therapeutics VTVT Stock Holding History

Boothbay Fund Management’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,941
Closed -$56K – 2703
2022
Q1 		$56K Hold
1,941
– – ﹤0.01% 2167
2021
Q4 		$77K Buy
+1,941
New +$104K ﹤0.01% 1744

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SQA
Simon Quick Advisors Morristown, New Jersey $2.19B AUM 17.29% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Boothbay Fund Management's VTVT Position: Q2 2022 in Review

Boothbay Fund Management sold out of vTv Therapeutics (VTVT) in Q2 2022, closing a stake of 1,941 shares — an estimated $56K sold.

Boothbay Fund Management first reported a position in VTVT in Q4 2021 and held it in 2 quarters. The position peaked at $77K in Q4 2021. 23 funds tracked by Wall St. Rank hold VTVT as of Q2 2022.

  • Boothbay Fund Management reported no remaining vTv Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 1,941 vTv Therapeutics shares in Q2 2022, an estimated $56K.
  • Boothbay Fund Management first reported a position in vTv Therapeutics in Q4 2021 and held it in 2 quarters.
  • Boothbay Fund Management's vTv Therapeutics position peaked at $77K in Q4 2021.
  • 23 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2022.

Based on Boothbay Fund Management's 13F filing for Q2 2022, filed 15 Aug 2022.